WO2002076505A1 - Remedes pour trouble de stress post-traumatique - Google Patents
Remedes pour trouble de stress post-traumatique Download PDFInfo
- Publication number
- WO2002076505A1 WO2002076505A1 PCT/JP2002/002513 JP0202513W WO02076505A1 WO 2002076505 A1 WO2002076505 A1 WO 2002076505A1 JP 0202513 W JP0202513 W JP 0202513W WO 02076505 A1 WO02076505 A1 WO 02076505A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mice
- receptor
- wild
- lps
- deficient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- PGE 2 has the drawback that the effects other than the intended effects can be side effects due to the wide variety of physiological activities.However, the role of each subtype is examined and only the subtype is effective. Research to overcome this deficiency by obtaining novel compounds is ongoing.
- the PGE have such PGE 2, although not selective for EPt receptors, since they have EP [receptors work ⁇ properties, considered as possible out to be used in the treatment of PTSD.
- EPt agonist or a non-toxic salt thereof is used for the treatment and / or prevention of PTSD, it is usually administered systemically or locally in an oral or parenteral form.
- Dosage varies depending on age, body weight, symptoms, therapeutic effect, administration method, treatment time, etc., but it is usually oral administration of lmg to 10 Omg per adult, once to several times a day. Or parenteral (preferably intravenous) once or several times daily, in the range of 0.1 mg to 1 Omg per adult, or 1 hour per day It is administered intravenously for a period of 24 hours.
- parenteral preferably intravenous
- a dose smaller than the above-mentioned dose may be sufficient in some cases, or administration outside the range may be necessary.
- the compound of the present invention When the compound of the present invention is administered, it is used as a solid composition, a liquid composition and other compositions for oral administration, an injection for parenteral administration, an external preparation, a suppository and the like.
- Solid compositions for oral administration include tablets, pills, capsules, powders, granules and the like.
- Capsules include hard capsules and soft capsules.
- the one or more active substances comprise at least one inert diluent, such as lactose, mannitol, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, Mixed with magnesium aluminate metasilicate.
- the composition may, in a conventional manner, contain additives other than inert diluents, such as lubricants such as magnesium stearate, disintegrants such as calcium cellulose glycolate, dalminic acid or aspartic acid.
- a solubilizing agent may be contained.
- Tablets or pills may be coated with a film of gastric or enteric substance such as sucrose, gelatin, hydroxypropylcellulose, hydroxypropylcellulose monophthalate, etc., if necessary, or with two or more layers. May be. Also included are capsules of absorbable materials such as gelatin.
- compositions for parenteral administration include topical solutions, ointments, liniments, suppositories for rectal administration, and vaginal administration containing one or more active substances and formulated in a conventional manner The first is included.
- FIG. 1 is a graph showing LPS-induced ACTH production using wild-type (BL 6) mice and EPi receptor-deficient (EP 1 _ / ⁇ ) mice.
- FIG. 2 is a graph showing the amount of LPS-induced ACTH produced by administration of ⁇ , an antagonist to wild-type mice.
- FIG. 4 is a graph showing the effect of EP and antagonist on LPS-induced automatic locomotor activity reduction in wild-type (WT) mice.
- Figure 7 is a graph showing the effect of EP t receptor deficiency in aggressive behavior lightning stimulation induced mice was performed using the receptor-deficient mice (black) and wild type (WT) mice (gray).
- LPS was administered intraperitoneally to C57BL / 6 mice at 0.1 mg / kg, placed in an acrylic cage (30 X 45 X 35 cm (height)), and stored from 8:00 pm to 8:00 the following morning. The activity for 12 hours was measured using a mouse activity meter and an Infrared photo beam counter (Neuroscience Co., Ltd., Tokyo, Japan). E Pi an evening gonist (same as in Experimental Example 1) was fed with food at 0.1% (W / W). Similarly, differences in locomotor activity due to LPS were compared between wild mice (WT) and EP, receptor-deficient mice.
- the vertical axis represents the spontaneous activity in the wild type (W T) Relative evaluation value based on the LPS non-administration group of mice as a reference (100). LPS administration to wild-type mice decreases locomotor activity, whereas deficient mice show a lower rate of locomotor activity.
- Wild mice (WT), EPi- or £ 3- receptor-deficient mice, or vanilla gonist (same as in Experimental Example 1) were administered intraperitoneally to lOmgZkg. We placed it on a platform (beaker) and observed whether it jumped off.
- Figure 5 shows the experimental results.
- the horizontal axis represents elapsed time
- the vertical axis represents the percentage of mice that jumped down.
- ⁇ marks indicate wild-type (Wild) mice (WT) and £? 3 receptor-deficient mice (EP3-/-), ⁇
- the mark indicates the data of EPt receptor-deficient mice, and the mark of Hata indicates the data of ⁇ , 7 antagonist-administered wild-type mice.
- the startle response to acoustic stimuli was performed using the SR-Lab system (San Diego instruments, CA, USA) in the same manner as reported by LNakamura et al. (Eur. J. Neurosci. 13, 179-189, 2001). . That is, a wild mouse (WT) or a receptor-deficient mouse is placed in the chamber, and after acclimating to a sound of 70 dB for 10 minutes, an acoustic stimulus of 80, 90, 10, 110 or 120 dB (at 40 ms) 6 times), and the presence or absence of a startle reaction for 200 ms was observed. The presence or absence of startle was determined by measuring the muscle contraction of the mouse from an electrode placed on the floor of the chamber.
- Figure 6 shows the experimental results.
- the horizontal axis represents the magnitude of the acoustic stimulus (dB)
- the vertical axis represents the response to the acoustic stimulus (startle response). Is shown.
- EP and receptor-deficient mice had an enhanced response to acoustic stimulation compared to wild mice, but this enhanced response to acoustic stimulation was observed when PTSD and dopamine metabolism in the brain were enhanced. Is known to be.
- Experimental Example 5 Effect of EP and receptor deficiency on aggressive behavior of mice induced by electric shock
- Figure 8 shows the experimental results.
- the vertical axis represents the ratio (Cumurative) (%) of the sniffing time to the total time.
- Wild (WT) mice marked with ⁇ ) show sniffing behavior and little aggressive behavior when cohabiting with young males. This behavior is perceived as a natural social behavior that is of interest to a young stranger.
- EP, receptor deficient mice showed a short sniffing time and frequently showed aggressive behavior at certain intervals.
- administration of EP and angyu gonist to wild mice shortened the sniffing time.
- FIGS. 9 and 10 The experimental results are shown in FIGS. 9 and 10.
- the vertical axis shows the ratio of metabolites to dopamine (DA) and serotonin (5-HT) in the cerebral cortex in EP, receptor-deficient mice (assuming that dopamine or serotonin is 100).
- DOPAC stands for 3,4-dihydroxyphenylacetic acid
- HVA stands for 3-methoxy-4-hydroxyphenylacetic acid, all of which are metabolites of DA (dopamine).
- 5-HIAA stands for 5-hydroxyindoleacetic acid, a metabolite of 5-HT (serotonin).
- EP t receptor-deficient mice in the same manner of the real as in Experimental Example 6 was administered haloperidol As a result of the experiment, it was confirmed that the time required to launch the first attack was extended, the number of attacks was reduced, and the total attack time was reduced.
- mice to which LPS was administered 2 hours before anesthesia were anesthetized with bentovalpital, and ice-cold saline was added to the blood vessel. After perfusion, the cells were treated with a zamponi solution (0.21%, 2,4,6-trinitrophenol and 2% paraformaldehyde in 0.1 M aqueous sodium phosphate (pH 7.3)).
- a zamponi solution 0.21%, 2,4,6-trinitrophenol and 2% paraformaldehyde in 0.1 M aqueous sodium phosphate (pH 7.3)
- mice brain and pituitary gland are excised, fixed in 4% paraformaldehyde (0.1 M sodium phosphate aqueous solution (PH7.3, phosphate buffer)) for 10 hours, and incubated under cooling in 25% sucrose solution did. Sections were prepared with a thickness of 30 m and used as specimens.
- paraformaldehyde 0.1 M sodium phosphate aqueous solution (PH7.3, phosphate buffer)
- the specimens were then pretreated with a solution of 1.5% normal goat serum in 0.1 M sodium phosphate (pH 7.3) containing 0.9% sodium chloride and 0.3% triton X-100 (PBS-triton) for 2 hours at room temperature. After that, the portion was first incubated with an anti-c-Fos ⁇ sagi polyclonal antibody (diluted 2000-fold; Ab-5, oncogen science) for 12 hours. Subsequently, the plate was incubated for 2 hours with a patinylated goat antibody against egret IgG (diluted 200-fold; Vector Laboratory), and finally avidin-piotin complex (diluted 100-fold) (Vector Laboratories ABC-PII kit; Vector Laboratory) for 1 hour at room temperature.
- PBS-triton triton X-100
- the following components were mixed in a conventional manner, and the mixture was tableted to give 100 tablets each containing G.5 mg of the active ingredient.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Forging (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Saccharide Compounds (AREA)
- Excavating Of Shafts Or Tunnels (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002440710A CA2440710C (en) | 2001-03-16 | 2002-03-15 | Medicine of post-traumatic stress disorder |
US10/471,805 US20040122100A1 (en) | 2001-03-16 | 2002-03-15 | Remedies for post-traumatic stress disorder |
JP2002575017A JPWO2002076505A1 (ja) | 2001-03-16 | 2002-03-15 | 心的外傷ストレス障害治療剤 |
DE60214987T DE60214987T2 (de) | 2001-03-16 | 2002-03-15 | Mittel gegen posttraumatische stresszustände |
EP02705269A EP1374899B1 (en) | 2001-03-16 | 2002-03-15 | Remedies for post-traumatic stress disorder |
US11/249,484 US20060058394A1 (en) | 2001-03-16 | 2005-10-14 | Medicine of post-traumatic stress disorder |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001075398 | 2001-03-16 | ||
JP2001-75398 | 2001-03-16 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/249,484 Division US20060058394A1 (en) | 2001-03-16 | 2005-10-14 | Medicine of post-traumatic stress disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002076505A1 true WO2002076505A1 (fr) | 2002-10-03 |
Family
ID=18932485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/002513 WO2002076505A1 (fr) | 2001-03-16 | 2002-03-15 | Remedes pour trouble de stress post-traumatique |
Country Status (7)
Country | Link |
---|---|
US (2) | US20040122100A1 (ja) |
EP (1) | EP1374899B1 (ja) |
JP (1) | JPWO2002076505A1 (ja) |
AT (1) | ATE340577T1 (ja) |
CA (1) | CA2440710C (ja) |
DE (1) | DE60214987T2 (ja) |
WO (1) | WO2002076505A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009133863A1 (ja) * | 2008-04-28 | 2009-11-05 | 国立大学法人浜松医科大学 | Ep1アゴニストを含有してなる免疫増強剤 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2667875A4 (en) * | 2011-01-24 | 2014-07-30 | Inceptum Res & Therapeutics Inc | COMPOSITIONS COMPRISING PROSTAGLANDIN FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11322709A (ja) * | 1998-05-06 | 1999-11-24 | Ono Pharmaceut Co Ltd | 6−オキソ−pge1化合物、それらの製造方法およびそれらを有効成分として含有するプロスタグランジンe2受容体作働薬 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004082517A2 (en) * | 2003-03-19 | 2004-09-30 | Bar Ilan University | Animal exhibiting ptsd-like behavior, per pct rule 4.3 |
-
2002
- 2002-03-15 US US10/471,805 patent/US20040122100A1/en not_active Abandoned
- 2002-03-15 WO PCT/JP2002/002513 patent/WO2002076505A1/ja active IP Right Grant
- 2002-03-15 EP EP02705269A patent/EP1374899B1/en not_active Expired - Lifetime
- 2002-03-15 DE DE60214987T patent/DE60214987T2/de not_active Expired - Lifetime
- 2002-03-15 JP JP2002575017A patent/JPWO2002076505A1/ja active Pending
- 2002-03-15 AT AT02705269T patent/ATE340577T1/de not_active IP Right Cessation
- 2002-03-15 CA CA002440710A patent/CA2440710C/en not_active Expired - Fee Related
-
2005
- 2005-10-14 US US11/249,484 patent/US20060058394A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11322709A (ja) * | 1998-05-06 | 1999-11-24 | Ono Pharmaceut Co Ltd | 6−オキソ−pge1化合物、それらの製造方法およびそれらを有効成分として含有するプロスタグランジンe2受容体作働薬 |
Non-Patent Citations (2)
Title |
---|
RANDALL P.K. ET AL.: "Effect of the benzodiazepine antagonist flumazenil in PTSD", BIOL. PSYCHIATRY, vol. 38, no. 5, 1995, pages 319 - 324, XP002954420 * |
TREPTOW K. ET AL.: "Effect of prostaglandins (PGE1 and PGE2) on central-nervous processes of conditional reflectory learning and the formation of a time-memory", ACTA BIOL. MED. GER., vol. 31, no. 1, 1973, pages 111 - 120, XP002954419 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009133863A1 (ja) * | 2008-04-28 | 2009-11-05 | 国立大学法人浜松医科大学 | Ep1アゴニストを含有してなる免疫増強剤 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2002076505A1 (ja) | 2004-07-15 |
CA2440710C (en) | 2009-08-18 |
US20040122100A1 (en) | 2004-06-24 |
EP1374899A1 (en) | 2004-01-02 |
DE60214987D1 (de) | 2006-11-09 |
EP1374899A8 (en) | 2004-03-10 |
DE60214987T2 (de) | 2007-09-06 |
US20060058394A1 (en) | 2006-03-16 |
EP1374899B1 (en) | 2006-09-27 |
CA2440710A1 (en) | 2002-10-03 |
ATE340577T1 (de) | 2006-10-15 |
EP1374899A4 (en) | 2004-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US12083116B2 (en) | Method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases | |
US20200030340A1 (en) | Drug therapy for preventing or treating glaucoma | |
JP2009521408A (ja) | Cdc2様キナーゼ(CLK)のモジュレータおよびその使用方法 | |
JP2004513921A (ja) | 減少された神経ステロイド活性に関連する疾患の治療でのgabaエンハンサー | |
AU2002253181B2 (en) | Use of selective COX-2 inhibitors for the treatment of urinary incontinence | |
Schwedler et al. | Native C-reactive protein induces endothelial dysfunction in ApoE−/− mice: implications for iNOS and reactive oxygen species | |
TWI331920B (en) | Unit dosage form for relieving or treating constipation in human patients | |
JP3852621B2 (ja) | 血管内皮細胞機能改善剤 | |
Jackowski et al. | Alterations in serotonin and neuropeptide Y content of cerebrovascular sympathetic nerves following experimental subarachnoid hemorrhage | |
JP2009221217A (ja) | 血管透過性亢進抑制剤 | |
TW201609640A (zh) | 吲哚基及吲哚啉基異羥肟酸於治療神經退化病症或認知缺乏之用途 | |
JPH05509293A (ja) | 不整脈および発作の治療における5―ht4受容体拮抗剤の使用 | |
WO2002076505A1 (fr) | Remedes pour trouble de stress post-traumatique | |
TW200400817A (en) | Use of selective EP4 receptor agonists for the treatment of liver failure loss of patency of the ductus arteriosus, glaucoma or ocular hypertension | |
US20220273660A1 (en) | Mek inhibitor for treatment of stroke | |
WO2003033004A1 (fr) | Agents permettant le traitement des affections abdominales inflammatoires | |
JP2003119138A (ja) | 間質性肺炎および/または肺線維症の予防治療剤 | |
JP4551649B2 (ja) | 血管透過性亢進抑制剤 | |
US9226926B2 (en) | Therapeutic agent for lower urinary tract disease | |
EP2129378B1 (en) | Therapeutic compositions comprising thromboserin or a salt thereof for use in the prevention or treatment of thrombosis in a patient at risk of bleeding | |
JPH0987174A (ja) | 鎮痛性および抗炎症性組成物 | |
WO2020082941A1 (zh) | 吉非罗齐及其衍生物用于治疗和/或预防神经退行性疾病的用途 | |
KR20230015999A (ko) | 펩스타틴 및 알긴산 또는 이의 염을 포함하는 조성물 및 이의 용도 | |
JP2024521282A (ja) | 抗うつ・抗不安の置換桂皮アミド化合物 | |
TW201347757A (zh) | 治療帶有腹瀉之腸躁症之方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002575017 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2440710 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10471805 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002705269 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002705269 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002705269 Country of ref document: EP |